Indivior launches $175M accelerated share buyback under $400M repurchase plan

Indivior Pharmaceuticals announced a $175 million accelerated share repurchase agreement with Barclays as part of its existing $400 million buyback program. The company made an upfront payment and will receive an initial delivery of over 3.7 million shares, with final shares repurchased based on stock price through June 2026. This move reflects Indivior's confidence in its long-term strategy and cash flow, and it does not affect the company's financial guidance. The remaining $100 million of the repurchase authorization may be used for future share buybacks depending on market conditions.